PROGRAM OVERVIEW
Join us for a national broadcast featuring 3 expert perspectives on patient-centered decision-making following COVID-19 exposure. Gain insights from clinicians who will discuss practical considerations for evaluating appropriate patients and navigating post-exposure management across care settings to make timely treatment decisions. Learn about a new oral therapy and how it can be an additional option when patients are concerned about COVID-19 exposure.
PROGRAM OBJECTIVES
- Review practical approaches to evaluating patients following COVID-19 exposure in primary care, urgent care, and long-term care settings
- Explore multidisciplinary perspectives on timely clinical decision-making for patients exposed to COVID-19
- Learn about a new oral therapy option and its potential role in post-exposure patient management of COVID-19
This promotional educational activity is brought to you by Shionogi, Inc. and is NOT certified for continuing medical education. The consultants are paid speakers for Shionogi, Inc. The speakers are presenting on behalf of Shionogi, Inc. and must present information in compliance with FDA requirements applicable to Shionogi, Inc.
Broadcast Schedule
The broadcast will be available at various times throughout the day, depending on your time zone. Reference the chart below for a complete list of broadcast times.
You may participate in any or all webcast sessions.
Available via
Main Event: Tuesday, October 20, 2026
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 12:15 PM | 11:15 AM | 10:15 AM | 9:15 AM |
| 1:15 PM | 12:15 PM | 11:15 AM | 10:15 AM |
| 3:15 PM | 2:15 PM | 1:15 PM | 12:15 PM |
| 7:00 PM | 6:00 PM | 5:00 PM | 4:00 PM |
| 8:30 PM | 7:30 PM | 6:30 PM | 5:30 PM |
| 10:00 PM | 9:00 PM | 8:00 PM | 7:00 PM |
INTENDED AUDIENCE
This broadcast is intended for US healthcare professionals who may treat patients following exposure to COVID-19. Please note that attendance at this program is strictly limited to healthcare professionals, and attendance by guests or spouses cannot be accommodated. Alcoholic beverages are not included as part of this speaker program. Attendees who wish to purchase alcohol may do so at their own expense. Shionogi is required to disclose any payments made to US licensed HCPs, including meals, pursuant to applicable federal and state laws.
Indication
XOCOVA (ensitrelvir) is indicated for post-exposure prophylaxis (PEP) of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.
Important Safety Infromation
Contraindications
XOCOVA is contraindicated in patients with a history of clinically significant hypersensitivity reactions to XOCOVA or any of its components. XOCOVA is also contraindicated when administered with drugs primarily metabolized by CYP3A for which elevated concentrations may be associated with serious and/or life-threatening reactions or when administered with strong CYP3A inducers because they may significantly reduce XOCOVA plasma concentrations leading to potential loss of virologic response.
Embryofetal Toxicity
Based on animal data, XOCOVA may cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential that XOCOVA may cause fetal harm. Verify pregnancy status of females of reproductive potential before initiating XOCOVA and advise using effective contraception during XOCOVA use and for 2 weeks after the final dose.
Risk of Serious Adverse Reactions Due to Drug Interactions
XOCOVA is a strong CYP3A inhibitor and an inhibitor of P-gp and BCRP. In patients receiving or initiating medications metabolized by CYP3A or transported by P-gp or BCRP, XOCOVA may increase plasma concentrations of those medications and may potentially lead to severe, life-threatening, or fatal events from increased exposure. CYP3A inducers may decrease concentrations of XOCOVA, leading to loss of therapeutic effect.
Before prescribing XOCOVA, review all concomitant medications to assess potential drug-drug interactions and determine if those medications require a dose adjustment, interruption, and/or additional monitoring. Consider the benefit of XOCOVA and whether risk of potential drug-drug interactions can be managed.
Hypersensitivity Reactions Including Anaphylaxis
Hypersensitivity reactions, including anaphylaxis, anaphylactic shock, and angioedema have been reported. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue XOCOVA and initiate appropriate treatment.
Lactation
There are no data on the presence of XOCOVA in human milk, effects on breastfed infants, or effects on milk production. XOCOVA was present in the milk of lactating rats. Advise women not to breastfeed while on XOCOVA and for 2 weeks after the final dose.
Adverse Reactions
The most common adverse events occurring in ≥1% of XOCOVA patients and at greater frequency than placebo, respectively, were headache (2.9% vs 2.6%), diarrhea (1.7% vs 1.3%), and cough (1.1% vs 0.6%).
Laboratory Abnormalities
Asymptomatic hemoglobin declines from baseline of >2 g/dL occurred in XOCOVA and placebo patients (3% vs 1%, respectively).
